{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:32:23Z","timestamp":1791477143908,"version":"4.3.4"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/pap.0b013e3181b4fffa","type":"journal-article","created":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T03:12:09Z","timestamp":1250824329000},"page":"267-282","source":"Crossref","is-referenced-by-count":501,"title":["Ovarian Low-grade and High-grade Serous Carcinoma"],"prefix":"10.1097","volume":"16","author":[{"given":"Russell","family":"Vang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie-Ming","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210202","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol"},{"key":"R2-1-20210202","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<893::AID-CNCR14>3.0.CO;2-W","article-title":"Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up","volume":"82","author":"Shimizu","year":"1998","journal-title":"Cancer"},{"key":"R3-1-20210202","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/PAS.0b013e3181a24354","article-title":"Defining the cut-point between low- and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis","volume":"33","author":"Ayhan","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R4-1-20210202","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00000478-199611000-00003","article-title":"Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors","volume":"20","author":"Burks","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"R5-1-20210202","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PAS.0b013e31802cbbe9","article-title":"The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis","volume":"31","author":"Dehari","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R6-1-20210202","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R7-1-20210202","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-04-0893","article-title":"Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas","volume":"10","author":"Hsu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R8-1-20210202","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.humpath.2005.07.014","article-title":"Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome","volume":"36","author":"Hsu","year":"2005","journal-title":"Hum Pathol"},{"key":"R9-1-20210202","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-08-3913","article-title":"Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas","volume":"69","author":"Kuo","year":"2009","journal-title":"Cancer Res"},{"key":"R10-1-20210202","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R11-1-20210202","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R12-1-20210202","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1158\/0008-5472.CAN-04-3625","article-title":"Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations","volume":"65","author":"Pohl","year":"2005","journal-title":"Cancer Res"},{"key":"R13-1-20210202","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1525-1438.2007.01039.x","article-title":"Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance","volume":"18","author":"Salani","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"R14-1-20210202","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1525-1438.2007.00820.x","article-title":"Differences of chemoresistance assay between invasive micropapillary\/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma","volume":"17","author":"Santillan","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R15-1-20210202","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R16-1-20210202","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"R17-1-20210202","doi-asserted-by":"crossref","first-page":"14004","DOI":"10.1073\/pnas.0504195102","article-title":"Amplification of a chromatin remodeling gene, Rsf-1\/HBXAP, in ovarian carcinoma","volume":"102","author":"Shih","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R18-1-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2007.01.030","article-title":"Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma","volume":"105","author":"Shvartsman","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R19-1-20210202","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0002-9440(10)62549-7","article-title":"Diverse tumorigenic pathways in ovarian serous carcinoma","volume":"160","author":"Singer","year":"2002","journal-title":"Am J Pathol"},{"key":"R20-1-20210202","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R21-1-20210202","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004347-200301000-00009","article-title":"Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor)","volume":"22","author":"Singer","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"R22-1-20210202","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation","volume":"29","author":"Singer","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R23-1-20210202","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00000478-200306000-00003","article-title":"Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases","volume":"27","author":"Smith Sehdev","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R24-1-20210202","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/PAS.0b013e31816fd555","article-title":"Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data","volume":"32","author":"Vang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R25-1-20210202","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/01.pas.0000213299.11649.fa","article-title":"Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion","volume":"30","author":"McKenney","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R26-1-20210202","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2004.03.004","article-title":"Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images","volume":"35","author":"Seidman","year":"2004","journal-title":"Hum Pathol"},{"key":"R27-1-20210202","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.humpath.2004.03.005","article-title":"Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives","volume":"35","author":"Bell","year":"2004","journal-title":"Hum Pathol"},{"key":"R28-1-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R29-1-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/gyno.2000.6066","article-title":"K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary","volume":"80","author":"Alvarez","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R30-1-20210202","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s004280050314","article-title":"In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential","volume":"434","author":"Haas","year":"1999","journal-title":"Virchows Arch"},{"key":"R31-1-20210202","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ygyno.2006.05.029","article-title":"KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants","volume":"103","author":"Mayr","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R32-1-20210202","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.1521","article-title":"In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours","volume":"202","author":"Sieben","year":"2004","journal-title":"J Pathol"},{"key":"R33-1-20210202","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2009","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"R34-1-20210202","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-04-2067","article-title":"Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors","volume":"64","author":"Ho","year":"2004","journal-title":"Cancer Res"},{"key":"R35-1-20210202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/hupa.2002.30212","article-title":"Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas","volume":"33","author":"Staebler","year":"2002","journal-title":"Hum Pathol"},{"key":"R36-1-20210202","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","article-title":"Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary","volume":"65","author":"Bonome","year":"2005","journal-title":"Cancer Res"},{"key":"R37-1-20210202","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","article-title":"Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms","volume":"5","author":"Nakayama","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"R38-1-20210202","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/sj.bjc.6604783","article-title":"KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer","volume":"99","author":"Nakayama","year":"2008","journal-title":"Br J Cancer"},{"key":"R39-1-20210202","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1158\/1078-0432.CCR-06-1059","article-title":"Gene expression signatures differentiate ovarian\/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma","volume":"12","author":"Davidson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R40-1-20210202","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.20408","article-title":"Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy","volume":"112","author":"Santin","year":"2004","journal-title":"Int J Cancer"},{"key":"R41-1-20210202","first-page":"277","article-title":"Genetic analysis of ovarian carcinoma histogenesis (Abstract)","volume":"80","author":"Pothuri","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R42-1-20210202","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jnci\/92.13.1088","article-title":"Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53","volume":"92","author":"Werness","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R43-1-20210202","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"R44-1-20210202","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R45-1-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jnci\/94.1.61","article-title":"Frequency of BRCA1 dysfunction in ovarian cancer","volume":"94","author":"Geisler","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R46-1-20210202","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","article-title":"Inactivation of BRCA1 and BRCA2 in ovarian cancer","volume":"94","author":"Hilton","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"R47-1-20210202","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/modpathol.3800306","article-title":"Origins and molecular pathology of ovarian cancer","volume":"18","author":"Bell","year":"2005","journal-title":"Mod Pathol"},{"key":"R48-1-20210202","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L","article-title":"Early de novo ovarian carcinoma. A study of fourteen cases","volume":"73","author":"Bell","year":"1994","journal-title":"Cancer"},{"key":"R49-1-20210202","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","article-title":"Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention","volume":"26","author":"Carlson","year":"2008","journal-title":"J Clin Oncol"},{"key":"R50-1-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"R51-1-20210202","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2559.2007.02938.x","article-title":"Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective","volume":"53","author":"Jarboe","year":"2008","journal-title":"Histopathology"},{"key":"R52-1-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R53-1-20210202","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R54-1-20210202","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J Pathol"},{"key":"R56-1-20210202","first-page":"663","article-title":"Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma","volume":"10","author":"Silva","year":"1997","journal-title":"Mod Pathol"},{"key":"R57-1-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.pgp.0000130049.19643.f6","article-title":"Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases","volume":"23","author":"Parker","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"R58-1-20210202","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ygyno.2006.05.030","article-title":"Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum","volume":"103","author":"Seidman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R59-1-20210202","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma","volume":"39","author":"Gilks","year":"2008","journal-title":"Hum Pathol"},{"key":"R60-1-20210202","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/PAS.0b013e318181a7ce","article-title":"Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion","volume":"32","author":"Yemelyanova","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R61-1-20210202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00004347-200110000-00002","article-title":"Ovarian mixed-epithelial carcinomas with a microcystic pattern and signet-ring cells","volume":"20","author":"Che","year":"2001","journal-title":"Int J Gynecol Pathol"},{"key":"R62-1-20210202","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0090-8258(03)00133-1","article-title":"Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system","volume":"89","author":"Ishioka","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R63-1-20210202","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/gyno.1993.1223","article-title":"Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary","volume":"50","author":"Bloss","year":"1993","journal-title":"Gynecol Oncol"},{"key":"R64-1-20210202","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0002-9378(50)90341-3","article-title":"Primary carcinoma of the fallopian tube","volume":"59","author":"Hu","year":"1950","journal-title":"Am J Obstet Gynecol"},{"key":"R65-1-20210202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0039-6109(16)41439-8","article-title":"Carcinoma of the fallopian tube","volume":"58","author":"Sedlis","year":"1978","journal-title":"Surg Clin North Am"},{"key":"R66-1-20210202","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1525-1438.2006.00590.x","article-title":"Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?","volume":"16","author":"Ayhan","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R67-1-20210202","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/1097-0142(20001115)89:10<2076::AID-CNCR7>3.0.CO;2-V","article-title":"Carcinoma of the fallopian tube","volume":"89","author":"Baekelandt","year":"2000","journal-title":"Cancer"},{"key":"R68-1-20210202","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ajog.2003.09.073","article-title":"Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study","volume":"190","author":"Barda","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R69-1-20210202","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/gyno.1996.0060","article-title":"Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma","volume":"60","author":"Ben-Baruch","year":"1996","journal-title":"Gynecol Oncol"},{"key":"R70-1-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0090-8258(03)00068-4","article-title":"Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study","volume":"89","author":"Bloss","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R71-1-20210202","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ejso.2004.08.005","article-title":"Prognosis of stage III or IV primary peritoneal serous papillary carcinoma","volume":"30","author":"Dubernard","year":"2004","journal-title":"Eur J Surg Oncol"},{"key":"R72-1-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1096-9098(200003)73:3<148::AID-JSO7>3.0.CO;2-U","article-title":"Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma","volume":"73","author":"Eltabbakh","year":"2000","journal-title":"J Surg Oncol"},{"issue":"1","key":"R73-1-20210202","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/ijgc-00009577-200602001-00020","article-title":"Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period","volume":"16","author":"Jaaback","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R74-1-20210202","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00004347-200404000-00011","article-title":"Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma","volume":"23","author":"Khalifeh","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"R75-1-20210202","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ygyno.2007.09.027","article-title":"Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary","volume":"107","author":"Moore","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R76-1-20210202","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","article-title":"An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2\/neu, and C-KIT in high-grade neoplasms","volume":"29","author":"O'Neill","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R77-1-20210202","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/modpathol.3800620","article-title":"Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis","volume":"19","author":"Reid-Nicholson","year":"2006","journal-title":"Mod Pathol"},{"key":"R79-1-20210202","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.pgp.0000172083.94934.1e","article-title":"Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein","volume":"24","author":"Armes","year":"2005","journal-title":"Int J Gynecol Pathol"},{"key":"R80-1-20210202","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-2559.2007.02682.x","article-title":"High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour","volume":"50","author":"O'Neill","year":"2007","journal-title":"Histopathology"},{"key":"R81-1-20210202","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.pas.0000213369.71676.25","article-title":"p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas","volume":"31","author":"Vang","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R82-1-20210202","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1309\/TDP92PQLDE2HLEET","article-title":"Mammaglobin vs. GCDFP-15: an immunohistologic validation survey for sensitivity and specificity","volume":"127","author":"Bhargava","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R83-1-20210202","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1097\/PAS.0b013e31816d71ad","article-title":"Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas","volume":"32","author":"Nonaka","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R84-1-20210202","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/01.pas.0000176429.88702.36","article-title":"Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary","volume":"29","author":"Tornos","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R86-1-20210202","doi-asserted-by":"crossref","first-page":"18739","DOI":"10.1073\/pnas.0604083103","article-title":"A BTB\/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival","volume":"103","author":"Nakayama","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R87-1-20210202","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","article-title":"Low-grade serous ovarian cancer: a unique disease","volume":"10","author":"Schmeler","year":"2008","journal-title":"Curr Oncol Rep"}],"container-title":["Advances in Anatomic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00125480-200909000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T18:31:25Z","timestamp":1633804285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00125480-200909000-00001"}},"subtitle":["Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems"],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/pap.0b013e3181b4fffa","relation":{},"ISSN":["1072-4109"],"issn-type":[{"value":"1072-4109","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}